One dose of an experimental drug cover offer lifetime treatment for people with high cholesterol, but its long-term safety is ...
An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.
A single infusion of CRISPR Therapeutics' experimental gene therapy was safe and reduced levels of harmful LDL cholesterol ...
In a small, short-term, Phase 2 clinical trial in adults, a first-of-its-kind medication reduced triglyceride levels in most ...
The single dose treatment helped patients lower “bad” cholesterol and triglyerides, both linked to heart disease ...
In a small, short-term, Phase 2 clinical trial in adults, a first-of-its-kind medication reduced triglyceride levels in most ...
Dangerously high levels of “bad” cholesterol and triglycerides may be reduced by gene editing, in what study researchers hope ...
In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...
In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like ...
A CRISPR-based gene editing therapy dramatically reduced levels of LDL cholesterol and triglycerides in patients with heart ...
Monthly olezarsen reduced triglycerides by 65% for people with severe hypertriglyceridemia, resulting in a greater than 85% ...
Triglycerides, a type of fat essential for energy, become a hidden danger when levels rise too high. Chronically elevated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback